Vesicle Trafficking Trio Wins Nobel

James Rothman, Randy Schekman, and Thomas Südhof share Nobel Prize in Medicine or Physiology.  

Oct 7, 2013
Kerry Grens

James Rothman, Randy Schekman, Thomas Südhof (left to right) NOBELPRIZE.ORG, H GOREN © HHMI, FISCH Randy Schekman returned from Germany last night only to be woken up after a few hours of sleep by his wife yelling, “This is it!” after she heard the phone ring. “I snapped to attention,” Schekman told The Scientist. “My heart started to race.” The voice on the other end told him he had won the Nobel Prize. Schekman, a professor at the University of California, Berkeley, and two others—James Rothman of Yale University and Thomas Südhof of Stanford University—share the Nobel in Physiology or Medicine this year for their discoveries in the fundamental mechanisms of trafficking cellular cargo.

Each has made major contributions to understanding the organization of how vesicle contents are discharged at the cell membrane. And each came to similar answers from different angles. Schekman focused on yeast genetics, while Rothman used biochemical methods in mammalian cells, and Südhof worked on synaptic vesicles in nerve terminals.

At 4:00 AM, EDT, this morning, Schekman called his best friend, Bill Wickner at Dartmouth College, to tell him the good news. Wickner told The Scientist he was not surprised to hear that Schekman and the others had won. “It's been clear” they would, said Wickner, who has had decades-long relationships with each of the winners. He even introduced Schekman to his wife.

“They're three very different people. Each is very intelligent, very purposeful and driven,” Wickner said. “I love each one of them. They're fun, they love to talk shop. They're good listeners as well as speakers.”

Südhof is well known for his role in discovering the neuronal SNARE proteins, involved in fusing vesicles to the membrane, and also for discovering the proteins involved in linking electrical activity in neurons to calcium flux and the triggering of SNAREs in vesicle fusion. Ege Kavalali, a University of Texas Southwestern neuroscientist, collaborated with Südhof on some of the research into synaptic cell adhesion. “[Südhof’s] most important contribution was that he actually found the mechanism for how calcium stimulation triggers neurotransmitter release,” he told The Scientist. “I’m exceptionally ecstatic and incredibly happy for him. It’s incredibly well deserved.”

Rothman developed an assay to measure membrane fusion. It “was a key to developing the biochemistry and biochemical analysis of in vitro trafficking,” said Wickner. Claudio Giraudo of the Children's Hospital of Pennsylvania, who worked in Rothman's lab for eight years, said that Rothman “revolutionized” the way people could ask questions by developing his in vitro fusion assays, “an approach nobody tried to do,” Giraudo added. “He's a very smart person I admire a lot.”

Some of the proteins Rothman identified turned out to be the same ones Schekman identified genetically using yeast. Jonas la Cour, a postdoc at the University of Copenhagen, recently worked in Schekman's lab as a visiting researcher. Schekman, who he described as “fun and accessible,” was welcoming and had invited la Cour to his home.

Schekman said the Nobel Prize will be a distraction for a while, but his focus will continue to be on his laboratory and as editor-in-chief of the new online publication, eLife.


January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.